Sponsor vs. CRO: how to choose AI for clinical data management
Key Takeaways:
- Large sponsors: Aim for a hybrid AI model. Own core analytics, integrate best-in-class platforms, and partner with CROs for execution.
- Mid-size biotech: Use platform-focused AI, and augment with CROs for operational depth.
- Emerging biotech: Maximize CRO-led AI. Keep only critical oversight internally.
- CROs: Let AI be your market differentiator. Showcase how it cuts costs and shortens timelines.
- All organizations: Understand your AI maturity stage and prioritize foundational investments, especially data standardization.
Are you leading clinical trials and unsure how to select the right AI model for clinical data management (CDM)? Your AI strategy will directly impact speed-to-decision, regulatory compliance, and overall trial performance. That’s true whether you’re a large global sponsor, a mid-size pharma, an emerging venture-backed biotech, or a contract research organization (CRO). This blog delivers a clear, actionable roadmap for navigating AI in CDM. We’ll help you steer your investment, ownership, and oversight with confidence.
Understanding AI ownership in clinical data management
Sponsors and CROs face a maze of choices today. Should you build, buy, or outsource AI? The answer depends on your size, portfolio complexity, strategic priorities, and regulatory needs. Here’s how to break it down, along with some recommended actions you should consider.
1. For large global sponsors:
The hybrid model advantage. If you’re running 50+ studies worldwide, managing multiple therapeutic areas, and have specialized data science resources, your AI priorities are clear. You need to maintain control, ensure standardization, and meet stringent regulatory expectations. A hybrid AI model is the gold standard.
This means owning critical elements like data standards, internal AI governance, and predictive modeling for cross-study analytics. Outsource data cleaning operations and reporting automation where specialized third-party tools offer proven efficiency. Leverage platform partners for functions such as risk-based monitoring and anomaly detection at the enterprise scale.
Avoid over-reliance on external CRO AI. Control the AI core for explainability and data consistency across all your trials.
2. For mid-size pharma and biotech:
Platform-centric AI with strategic augmentation. Are you managing between 5 and 25 studies with a lean internal team? Your priority is trial velocity without piling on infrastructure cost. The ideal approach involves adopting platform-centric AI for core CDM activities, such as automated data queries, aggregation, and predictive modeling. Use CROs for operational augmentation, especially in areas like risk monitoring and reporting. Own only what’s necessary to stay agile. Think light-touch governance, not heavy investments.
Skip building proprietary AI or infrastructure unless you plan to rapidly expand trial volume. Focus on workflow integration and partnership synergy.
3. For emerging and small biotech:
CRO-led AI with light oversight. If you run 1 – 5 trials and outsource most operational activities, speed and simplicity are non-negotiable. Your best response includes relying on CRO-driven AI for data cleaning, query generation, and risk monitoring. Retain oversight only to validate outputs and ensure alignment with top-level milestones. Finally, avoid custom AI builds and complex data lakes that you won’t need. Let your CROs bring the tech muscle.
Optimize for efficiency and speed, not long-term system complexity. Delegate as much as possible but keep enough internal knowledge for informed oversight.
4. For CROs:
AI as a differentiator. Today, AI is a leading factor in winning clinical study RFPs. Your AI strategy should align with your market segment.
- Large CROs – Integrate AI deeply within your platforms and analytics. Offer proprietary value-adds.
- Mid-sized and niche CROs – Partner with technology vendors for AI capabilities such as automated queries or generative reporting. Highlight these as competitive differentiators.
- Innovators – Excel in data review automation and generative document drafting. Clients increasingly expect these efficiencies.
All CROs should make their AI value proposition part of every pitch. Clearly communicate how AI reduces timelines and manual effort for your clients.
The AI maturity roadmap
Where are you and what comes next? Every sponsor and CRO is at a different place on the AI maturity curve. Here’s how it breaks down, with key use cases and what the next level looks like.
Level 0: Manual / Reactive CDM
- Manual edit checks, high errors, slow data cleaning. This level is typical of small biotech or low-maturity CROs.
- Next Step: Move to rule-based automation as quickly as possible.
Level 1: Rule-Based Automation
- Configured edit checks, basic dashboards, standard query automation.
- Next Step: Start standardizing data and introduce machine learning for anomaly detection.
Level 2: ML-Assisted Data Quality
- AI-driven query suggestion, anomaly detection, early risk signals.
- Next Step: Centralize data across studies and enable portfolio-level risk monitoring.
Level 3: Predictive and Risk-Driven CDM
- Site risk scoring, cross-study learning, forecasting timelines.
- Next Step: Add generative AI for automated document drafting and conversational analytics.
Level 4: Generative and Augmented CDM
- Large language models for text-to-query, AI copilots, narrative automation.
- Next Step: Work towards orchestration where AI coordinates workflows and shifts humans into oversight roles.
Level 5: Autonomous / Self-Optimizing CDM
- AI agents resolve discrepancies, adapt monitoring, and manage workflows in real time.
- Next Step: Not yet industry standard. Early adoption among innovation labs only.
Assess your organization’s current level. The hardest jump is from Level 1 to Level 2. Focus on data standardization, integration, and building trust — internally or with partners — in your AI outputs.
The decision framework: 5 essential questions before you invest
To validate your AI strategy, ask:
Do you need cross-study insights, or just operational efficiency?
The broader your portfolio, the more platform-level and internal AI you need.
Are you growing rapidly or staying focused on a few studies?
Rapid scaling justifies AI infrastructure. Steady-state companies should leverage external platforms and CROs.
Do regulators need to see explainable AI documentation?
The stricter your regulatory environment, the more you must own AI governance and validation.
Is your CRO portfolio standardized?
Standardized models allow for more outsourcing. Heterogeneous portfolios require hybrid or internal AI.
Do you see AI as a source of competitive advantage or simply a tool for efficiency?
If it’s a differentiator, invest in proprietary or hybrid models. Otherwise, outsource for cost and speed.
Next steps
In the rapidly evolving world of clinical data management, choosing the right AI path isn’t just about keeping up. It’s about gaining real, measurable advantages. Whether you’re a sponsor safeguarding portfolio data or a CRO competing for the next big project, the AI ownership model, maturity roadmap, and strategic fit are all essential. The boldest organizations harness AI as more than technology. It’s their competitive advantage.
Ready to future-proof your clinical data management? Vita Global Sciences (VGS), a Kelly® company, brings deep expertise in guiding sponsors and CROs through the AI decision maze. We can help you accelerate timelines, reduce risk, and achieve regulatory success. Contact VGS today for a tailored consultation and see how our solutions can advance your clinical trial outcomes.
FAQs on choosing AI for clinical data management
Q: How do I know which AI capabilities to keep in-house vs. outsource?
A: Align with your portfolio size and regulatory requirements: own AI when you need control, outsource when speed and cost dominate.
Q: What are the most important steps for moving up the AI maturity curve?
A: Data standardization and AI governance. Without these, scaling from basic automation to predictive or generative AI is impossible.
Q: Is building custom AI ever justified?
A: Only if you’re rapidly scaling and see AI as a competitive differentiator. Otherwise, secure best-in-class capabilities through partners or platforms.
Q: How can CROs use AI to win more clients?
A: By demonstrating clear reductions in manual effort, shortened cycle times, and regulatory-ready outputs enabled by embedded AI capabilities.
